<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704496</url>
  </required_header>
  <id_info>
    <org_study_id>25325</org_study_id>
    <secondary_id>25325</secondary_id>
    <nct_id>NCT00704496</nct_id>
  </id_info>
  <brief_title>The Effect of Pseudoephedrine on Rhinitis and Sleep</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a
      decongestant, will decrease nasal congestion leading to increased patency of the nose and a
      decrease in nighttime sleep fragmentation in individuals with year round perennial allergic
      rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and
      fatigue.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of sleep associated with the use of pseudoephedrine as compared to the placebo</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of daytime somnolence with pseudoephedrine as compared to placebo</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Rhinitis</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pseudoephedrine is a 240 mg PO per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine</intervention_name>
    <description>Pseudoephedrine is a 240 mg PO per day</description>
    <arm_group_label>Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65.

          2. History of allergic rhinitis.

          3. The ability to be placed on placebo without significant compromise in the quality of
             life.

          4. General good health.

          5. Ability to comply with the protocol and sign an informed consent.

          6. Have daytime sleepiness by history.

          7. Have poor sleep by history.

          8. Have fatigue by history.

          9. Have a skin test or RAST test to a perennial allergen (indoor mold, dog, cat, mite)
             with correlating symptoms.

        Exclusion Criteria:

          1. Age fewer than 18 or over 65 years.

          2. A history of sleep apnea.

          3. Atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma.

          4. Non-allergic rhinitis.

          5. Hypertension

          6. Diabetes Mellitus

          7. Inability to tolerate pseudoephedrine

          8. Significant other diseases as determined by the investigator.

          9. Use of a research medication within 30 days.

         10. Use of a nasal steroid or topical antihistamine or decongestant within 30 days.

         11. Use of beta-blockers, antidepressants, oral decongestants, oral steroids, or
             H2-blockers.

         12. Excessive use of alcohol or drug abuse.

         13. Inability to stop medication use during run-in period.

         14. Use of an oral antihistamine within 1 week of enrollment.

         15. Failed to have benefit when pseudoephedrine was used for rhinitis or asthma in the
             past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Craig, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy J Craig, D.O.</last_name>
    <phone>717-531-6525</phone>
    <email>tcraig@psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J Craig, D.O.</last_name>
      <phone>717-531-6525</phone>
      <email>tcraig@psu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 24, 2008</lastchanged_date>
  <firstreceived_date>June 24, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Timothy Craig, D.O.</name_title>
    <organization>Penn State University</organization>
  </responsible_party>
  <keyword>Sleep, Pseudoephedrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
